Delivery Order SPE2DB22D2007-SPE2DB25FJ4UN
Award Date 9/9/25
Potential Completion Date 9/10/25
Potential Value $4.2K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $3,392.62 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (16-count unit dose packaging) on July 21, 2025, with completion scheduled for July 22, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and is performed at the contractor's corporate office location in Conshohocken, Pennsylvania. UBRELVY (ubrogepant) is a calcitonin gene-related peptide (CGRP) receptor...
- The Defense Logistics Agency awarded a delivery order valued at $5,427.25 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablet unit dose packs (16 count). This competitively awarded, firm fixed-price delivery order has an ultimate completion date of August 25, 2025. UBRELVY (ubrogepant) is a calcitonin gene-related peptide receptor antagonist indicated for acute migraine treatment. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,603.68 to AmerisourceBergen Drug Corp for UBRELVY 50 mg tablets (100 unit-dose packs) on August 13, 2025, with an ultimate completion date of August 14, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. UBRELVY (ubrogepant) is a prescription medication used for acute...
- The Defense Logistics Agency awarded a $5,423.70 delivery order to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (10-unit dose packages) with a completion deadline of September 2, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The work will be performed at the contractor's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $1,956.25 to AmerisourceBergen Drug Corp for UBRELVY 100 MG tablets (10 unit-dose packages) under a firm fixed-price contract. The award, issued on August 21, 2025, with an ultimate completion date of August 22, 2025, represents a non-set-aside competitive award. UBRELVY (ubrogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist used for acute migraine treatment, reflecting the Defense Logistics Agency Medical...
- The Defense Logistics Agency awarded a delivery order valued at $2,199.96 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (10 unit dose packages) on August 14, 2025, with an ultimate completion date of August 15, 2025. This is a firm fixed price delivery order with no set-aside designation, awarded competitively under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging on July 29, 2025, with a ceiling value of $2,706.94 and ultimate completion date of July 30, 2025. UBRELVY is a calcitonin gene-related peptide (CGRP) receptor antagonist used for acute migraine treatment. This delivery order was competitively awarded without set-aside designation and carries firm fixed pricing. The contract is performed at...
- The Defense Logistics Agency awarded a $2,347.18 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of UBRELVY 100 mg tablets in unit dose packages of 10. This is a firm fixed-price delivery order with no set-aside designation, representing a competitively awarded contract. The pharmaceutical product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 19, 2025. UBRELVY (ubrogepant) is a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,270.92 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (10-count unit dose packaging) with an ultimate completion date of August 1, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through an open process. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. UBRELVY is a migraine treatment medication,...
- The Defense Logistics Agency awarded a $16,964.04 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging (10-count). The contract, which is a non-competitive delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, has an ultimate completion date of September 11, 2025. UBRELVY is an FDA-approved acute migraine treatment...